Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an ...

Researchers at the University of Houston, in collaboration with Baylor College of Medicine, are developing new devices for ...

Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of careTriplet Combination with mipletamig continues to outperform ...

Vitamins have been a part of our lives for generations, haven't they? From the bright orange chewable vitamin C tablets of childhood to the little capsules tucked into kitchen cabinets, they've always ...

Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of careTriplet Combination with mipletamig continues to outperform do ...

The incidence of leukemic conversion from PNH is estimated to be less than 3%. A patient had an extremely rare case of leukemic conversion from paroxysmal nocturnal hemoglobinuria (PNH). A report of ...

Researchers at the University of Houston, in collaboration with Baylor College of Medicine, are developing new devices for treating children with ...

Giving blood regularly may not just be saving the lives of other people, it could also be improving your own blood's health ...

The combined use of two well-known active substances can fight leukemic cells and limit their spread. This is the result of a study conducted by the Karl Landsteiner University of Health Sciences (KL ...

Despite multiple treatments for eczema and pityriasis alba, a child’s skin condition worsened until a biopsy revealed mycosis ...

Open label study in forty AML and MDS patients Study financed by the US Department of Defense Cantargia (Cantargia AB; Nasdaq ...